The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Related party payable | - | -31,000 |
| Net loss | -2,895,585 | -6,327,213 |
| Changes in fair value of warrant liability | -79,447 | 107,961 |
| Interest expense | 1,220,632 | 2,285,080 |
| Loss on conversion of note payable | 0 | 448,802 |
| Stock-based compensation | 639,586 | 885,695 |
| Prepaid expenses | 13,549 | -21,316 |
| Other liabilities | - | 0 |
| Subscriptions receivable | -10,222 | - |
| Accounts payable | 22,274 | -51,055 |
| Accrued expenses | 7,655 | -861,764 |
| Commitment fee | - | 0 |
| Related party payable | -31,000 | - |
| Net cash used in operating activities | -1,088,212 | -3,522,178 |
| Proceeds from fpa settlement | - | 140,572 |
| Proceeds from convertible promissory note, net of issuance cost | 0 | 2,150,000 |
| Proceeds from sales of stocks and warrants, net | 0 | 11,394,218 |
| Acquisition of drug license | - | 0 |
| Proceeds from stock subscriptions | 500,000 | - |
| Net cash used in (provided by) investing activities | - | 0 |
| Proceeds from sale of preferred b shares | 0 | 500,000 |
| Payments on notes payable | 0 | 2,730,182 |
| Payments for deferred financing costs | 25,000 | 25,000 |
| Proceeds from fpa settlement | 140,572 | - |
| Merger proceeds net of transaction cost | - | 0 |
| Payments on financed director and officer insurance | 0 | 40,225 |
| Proceeds from at-the-market sales of common shares | -494,700 | 500,000 |
| Net cash provided by financing activities | 5,300 | 11,889,383 |
| Net change in cash | -1,082,912 | 8,367,205 |
| Cash and cash equivalents at beginning of period | 63,741 | - |
| Cash and cash equivalents at end of period | 7,348,034 | - |
Klotho Neurosciences, Inc. (KLTO)
Klotho Neurosciences, Inc. (KLTO)